Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Total Voting Rights

30 Sep 2024 17:00

RNS Number : 3109G
Biome Technologies PLC
30 September 2024
 

 

30 September 2024

 

Biome Technologies plc

("Biome", the "Company" or the "Group")

 

Total Voting Rights

 

Biome Technologies plc, a leading bioplastics and radio frequency technology business, announces that the Company's issued ordinary share capital as at the date of this announcement comprises 51,555,814 ordinary shares of 5 pence each with one voting right each ("Ordinary Shares"). The Company does not hold any shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company is 51,555,814.

 

The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

-Ends-

 

For further information please contact:

Biome Technologies plc

Paul Mines, Chief Executive Officer

Donna Simpson-Strange, Company Secretary

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

 

Allenby Capital

David Hart/Alex Brearley/Lauren Wright (Nominated Adviser)

Kelly Gardiner/Tony Quirke (Sales and Corporate Broking)

www.allenbycapital.com

Tel: +44 (0) 20 3328 5656

 

About Biome

Biome Technologies plc is an AIM listed, growth-orientated, commercially driven technology group. Our strategy is founded on building market-leading positions based on patented technology and serving international customers in valuable market sectors. We have chosen to do this by developing products in application areas where the value-added pricing can be justified and are not reliant on government legislation. These products are driven by customer requirements and are compatible with existing manufacturing processes. They are market rather than technology-led.

 

The Group comprises two divisions, Biome Bioplastics ("Bioplastics") and Stanelco RF Technologies Limited ("RF Technologies").

 

Biome Bioplastics is a leading developer of highly-functional, bio-based and biodegradable plastics. The division's mission is to produce bioplastics that challenge the dominance of oil- based polymers.

 

RF Technologies designs, builds and services advanced radio frequency (RF) systems. Dielectric and induction heating products are at the core of a product offering that ranges from portable sealing devices to large furnaces for the fibre optics markets.

 

www.biometechnologiesplc.com www.biomebioplastics.com and www.thinkbioplastic.com www.stanelcorftechnologies.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRFZGFLKGGGDZM
Date   Source Headline
27th Mar 20192:05 pmRNSSecond Price Monitoring Extn
27th Mar 20192:00 pmRNSPrice Monitoring Extension
13th Mar 20191:54 pmRNSHoldings in Company
24th Jan 20197:00 amRNSPre-close Trading Statement
31st Dec 20187:00 amRNSTotal Voting Rights
10th Dec 20182:35 pmRNS2017 Long Term Incentive Plan - First Vesting
6th Dec 20187:00 amRNSGrant funding from Innovate UK
23rd Nov 201812:38 pmRNSBiome to present at Mello London
1st Nov 20187:00 amRNSTrading update
3rd Sep 20187:00 amRNSInterim Results
23rd Jul 20187:00 amRNSTrading Update
31st May 20185:00 pmRNSTotal Voting Rights
2nd May 20184:13 pmRNSIssue of shares to directors & PDMR shareholdings
2nd May 20183:27 pmRNSProposed issue of shares to directors and dealings
24th Apr 201810:40 amRNSResult of Annual General Meeting
24th Apr 20187:00 amRNSTrading update
28th Mar 20181:52 pmRNSNotice of AGM and Annual Report and Accounts
27th Mar 20187:00 amRNSPreliminary Results
19th Feb 20182:05 pmRNSSecond Price Monitoring Extn
19th Feb 20182:00 pmRNSPrice Monitoring Extension
25th Jan 20187:00 amRNSPre-close Trading Statement
21st Dec 20177:00 amRNSNew LTIP and option grant
1st Nov 20177:00 amRNSTrading Update
4th Sep 20177:00 amRNSHalf-year Report
26th Jul 20179:30 amRNSDirector/PDMR Shareholding
25th Jul 20174:50 pmRNSDirector/PDMR Shareholding
24th Jul 20177:00 amRNSTrading Update
24th Apr 201710:45 amRNSResult of AGM
24th Apr 20177:00 amRNSTrading Update
31st Mar 20172:50 pmRNSNotice of AGM and Annual Report and Accounts
29th Mar 20177:00 amRNSPreliminary Results
20th Jan 20177:00 amRNSPre-close Trading Statement
18th Jan 20177:00 amRNSSettlement Agreement
2nd Nov 20167:00 amRNSTrading Update
31st Aug 20167:00 amRNSHalf-year Report
27th Jun 20167:00 amRNSTrading Update
25th Apr 201612:34 pmRNSResult of Annual General Meeting
25th Apr 20167:00 amRNSTrading Update
1st Apr 201610:42 amRNSNotice of AGM and Annual Report and Accounts
30th Mar 20167:00 amRNSFinal Results
26th Jan 20167:00 amRNSPre-close Trading Statement
3rd Nov 20157:00 amRNSTrading Statement
2nd Sep 20157:00 amRNSInterim Results
23rd Jul 20157:00 amRNSTrading Update
19th Jun 20159:00 amRNSNew Contract
27th Apr 20154:46 pmRNSResult of AGM
27th Apr 20157:00 amRNSTrading Update
27th Mar 20153:43 pmRNSNotice of Annual General Meeting
25th Mar 20157:00 amRNSPreliminary Results
19th Feb 20153:26 pmRNSFunding Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.